AC Immune SA (ACIU) Stock: A Biotech Stock That’s Making Its Way For The Top

0

AC Immune SA (ACIU) is gaining in the market in today’s trading session. The company, one that is focused in the biotechnology sector, is presently priced at $5.25 after heading up 6.06% so far today. When it comes to biotechnology companies, there are several aspects that have the potential to generate gains in the market. One of the most common is news. Here are the recent trending headlines relating to ACIU:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-15-19 08:35AM AC Immune (ACIU) Lags Q1 Earnings and Revenue Estimates
07:36AM AC Immune: 1Q Earnings Snapshot
07:00AM AC Immune Reports Q1 2019 Financial Results and Business Update
May-08-19 01:27PM Heres What Hedge Funds Think About AC Immune SA (ACIU)
Apr-24-19 10:33AM AC Immune (ACIU) to Report Q1 Results: Wall Street Expects Earnings Growth

Nonetheless, any time investors are making an investing decision, prospective investors should focus on much more than just news, especially in the generally speculative biotech space. Here’s what’s happening with AC Immune SA.

Recent Moves From ACIU

Although a single session gain, like the move that we’re seeing from AC Immune SA may lead to excitement in some investors, a single session move alone shouldn’t be the reason for a decision to, or not to, invest in a stock. It is always a good idea to dig into trends experienced by the stock further out than a single trading day. In the case of ACIU, here are the returns that we’ve seen:

  • Past 5 Trading Sessions – In the past seven days, ACIU has seen a change in price in the amount of 2.14%.
  • Past 30 Days – The monthly returns from AC Immune SA has been 1.74%.
  • Past 3 Months – Over the past 3 months, the stock has generated a ROI that works out to 13.39%
  • Past 6 Months – Over the previous 6 months, we have seen a performance that equates to -52.91% from the stock.
  • This Year So Far – Since the the first trading session of this year ACIU has resulted in a return of -44.44%.
  • Annually – Finally, throughout the last year, we have seen movement that comes to -46.97% out of ACIU. Over this period, the stock has sold at a high price of -69.83% and a low of 61.54%.

Important Ratios

Looking at a few ratios having to do with a stock can provide investors an understanding of just how dangerous and/or potentially profitable a pick might be. Below are a few of the key ratios to think about when looking at ACIU.

Short Ratio – The short ratio is a measure of short interest. As the short ratio climbs, it means that more investors believe that the price of the stock is headed for declines. Across the sector, biotechnology stocks can have a higher short ratio. However, we also tend to see quite a few short squeezes in the sector. Nonetheless, in relation to AC Immune SA, the stock’s short ratio amounts to 2.24.

Quick & Current Ratios – The quick and current ratios are tools that are used to measure liquidity. Basically, they measure If a company is able to pay for its debts as they mature based on quick assets or current assets. In the biotech sector, several companies are heavily reliant on the continuation of investor support, these ratios can seem upsetting. Nonetheless, several good picks in the biotechnology sector do have strong quick and current ratios. As far as ACIU, the quick and current ratios add up to 5.10 and 5.10 respectively.  

Book To Share Value – The book to share value compares the current book value of assets currently owned by the company to the price of shares. In this particular case, that ratio works out to 3.59.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the value of the company’s stock. Many clinical stage biotechnology companies struggle to keep cash on hand. So, if you’re interested in a biotech stock, this is an important ratio to consider. In this case, the cash to share value ratio is 4.53.

Analyst Opinions Of AC Immune SA

Although it’s not a smart idea to unknowingly follow the thoughts of analysts, it is a smart idea to consider their thoughts when validating your own before making investment decisions in the biotech industry. Below you’ll find the most recent moves that we have seen from analysts when it comes to ACIU.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-01-19 Downgrade UBS Buy → Neutral
Jan-04-19 Initiated UBS Buy
Apr-05-18 Initiated H.C. Wainwright Buy $18
Mar-23-18 Downgrade Credit Suisse Outperform → Neutral
Oct-18-16 Initiated Leerink Partners Outperform

Is Big Money Interested in AC Immune SA?

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in ACIU, here’s what we’re seeing:

Institutions own 27.10% of the company. Institutional interest has moved by -14.23% over the past three months. When it comes to insiders, those who are close to the company currently own 51.67% percent of ACIU shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

What You Need To Know About Share Counts

Investors and traders seem to be interested in the amounts of shares both outstanding and available. With respect to AC Immune SA, there are currently 67.30M with a float of 32.65M. This means that out of the total of 67.30M shares of ACIU that are out there today, 32.65M are available to trade hands in the public space.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to ACIU, the short percent of the float is 1.76%.

Financial Performance

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.88. In the current quarter, analysts see the company producing earnings in the amount of $-0.22. Over the last 5 years, ACIU has generated revenue in the amount of $-3.60% with earnings coming in at -31.60%. On a quarter over quarter basis, earnings have seen movement of 562.70% and revenue has seen movement of 5046.90%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

As a computer, I am heavily dependent on humans. A human built me! Even though my creator made it possible for me to learn by myself, it is a lot easier to learn when I receive human feedback. Below this content, you will find a section for comments. If you’d like for me consider other data, tweak the way in which I communicate, look at data from a different perspective, or you’re interested in telling me anything else, I want to know. If you’ve got something to offer leave a comment below. I’ll process that comment and I will use it to become a better artificial intelligence to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here